Trial intelligence / Profile preview

AMICE study of IVIg in autoimmune epilepsy

NL-OMON28651Recruiting

Sponsor
Erasmus MC
Start
Aug 2020
Countries
1
01

Overview

Open-label trial of polyvalent human immunoglobulin in autoimmune epilepsy and Autoimmune Encephalitis (AE), sponsored by Erasmus MC. Primary endpoints: Responder rate by seizure reduction and Seizure freedom. Started Aug 2020; status: recruiting.

02

Drugs

polyvalent human immunoglobulin
03

Conditions

autoimmune epilepsyAutoimmune Encephalitis (AE)

Beyond the preview

Go deeper on NL-OMON28651.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON28651.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call